With M2Gen Investment, Hearst Seeks to Marry Genomic Cancer Data With Clinical Records

CHICAGO (GenomeWeb) – Media company Hearst took a significant leap into precision medicine last week by investing $75 million in M2Gen, the health informatics subsidiary of Moffitt Cancer Center in Tampa, Florida.

It turns out that Hearst has been eyeing precision medicine for some time to round out its roster of healthcare data entities that have a common thread: they aim to optimize processes of care. “Every one of our companies is about guiding care across the patient’s journey,” said Greg Dorn, president of Hearst Health.

Those holdings include drug knowledge database First Databank (branded as FDB), order set-focused clinical decision support content provider Zynx Health, clinical guideline publisher MCG (formerly called Milliman Care Guidelines), and Homecare Homebase for home healthcare management. Last year, Hearst bought Tampa-based MedHOK (Medical House of Knowledge), which gives Medicare Advantage and Medicaid managed care plans a “360 view of patients who are insured in those plans,” according to Richard Malloch, president of Hearst Business Media, the unit that includes Hearst Health.

“They have a common theme around care guidance,” Malloch said of these companies. “We’re trying to insinuate ourselves into those [care] moments with the best curated evidence to help clinicians and everyone who touches

Be the first to comment

Leave a Reply

Your email address will not be published.


*